

## Wealth Management & Private Banking Review 2Q25 / 6m25


The aggregate operating revenue reached \$42bn in 2Q25, up 10% y/y and only a shade below 1Q25. Year-to-date, revenue totalled \$85bn, +10% y/y.

Investment management fees, up 12% and 17% y/y respectively, were the key drivers in 2Q25. Contrary to consensus expectations, net interest income grew, albeit very slightly and only due to three large banks aggressively expanding their lending business. Cash reserves dropped sharply amid falling interest rates, but demand for gold (including in tokenised form) and alternatives continues to rise.


Regionally, revenue growth in Americas and APAC outpaced EMEA - again, and by a wide margin. We expect EMEA will continue to lag in 2H25, but the differential may become smaller over the next year as several banks are making significant investments in Europe and the Middle East. That said, a shortage of experienced relationship managers in the Middle East is straining growth and profitability. The fastest-growing client segments in 2Q25 were HNWI High (AuM \$10-25m) and mass-affluent (\$200k-\$1m).

Operating costs are tightly controlled (especially in EMEA) and increasingly focused on client-facing staff, as well as targeted AI tools and link-ups with specialist providers. The aggregate pre-tax profit totalled \$10bn in 2Q25: unchanged from 1Q25 but 10% ahead of the prior-year period.

AuM advanced 14% y/y, though primarily due to strong market valuations and FX effects, rather than new money. The growth in HNWI Low AuM (\$1-10m) narrowly outpaced other client categories.



#### % change share of peer group operating revenue and pre-tax profit (6m25 / 6m24)



Notes: (1) Tricumen-normalised product definitions and allocations apply. (2) Operating revenue and pre-tax profit excludes one-offs. (3) IM = Investment Management fees. Advisory = client-led; Discretionary = advisor-led. (4) Clients: Mass-affluent = \$200k-\$1m AuM; HNWI Low = \$1-10m AuM; HNWI High = \$10-25m; UHNWI & GFO = \$25m+. (5) RoAuM = year-to-date operating revenue / end-of-period AuM.



# **Rankings: Operational performance**


_	•	•			
Pre-tax profit (US\$m)			Pre-tax profit margin (%)		
	Rank	6m25 / 6m24		Rank	6m25 / 6m24
	6m25	(movement)		6m25	(movement)
MS	#1	∑	DBS	#1	$\sim$
JPM	#2	<u>S</u>	JPM	#2	$\sim$
UBS	#3	$\supset$	HSBC	#3	$\sim$
BAML	#4	₽	GS	#4	$\sim$
HSBC	#5	<u>S</u>	MS	#5	$\sim$
RBC	#6	<b>^</b>	RBC	#6	•
œ	#7	•	BAML	#7	•
Operating revenue / FO FTE			Operating revenue / AuM (eop)		
	Rank	6m25 / 6m24		Rank	6m25 / 6m24
	6m25	(movement)		6m25	(movement)
DBS	#1	<b>1</b>	RBC	#1	<b>1</b>
œ	#2	₽	WFC	#2	1
STAN	#3	$\sim$	LPL	#3	<b>S</b>
AB	#4	$\supset$	DBS	#4	<u>∑</u>
LPL	#5	$\supset$	HSBC	#5	•
JPM	#6	$\supset$	BAML	#6	•
UBS	#7	Z.	DBK	#7	•
NNM (eop)			eop NNM % eop AuM		
	Rank	6m25 / 6m24		Rank	6m25 / 6m24
	6m25	(movement)		6m25	(movement)
JPM	#1	<b>1</b>	STAN	#1	$\Sigma$
LPL	#2	•	JPM	#2	•
BAML	#3	•	LPL	#3	∑
GS	#4	Ų.	DBS	#4	$\sim$
STAN	#5	<u>S</u>	GS	#5	∑
HSBC	#6	$\supset$	HSBC	#6	$\supset$
DBS	#7	$\supset$	DBK	#7	•

Notes: (1) Tricumen-normalised product definitions and allocations apply. Revenue and pre-tax profit exclude one-offs. All financials are shown in US\$. (3) In-scope: clients with AuM in excess of \$200k. (4) FO FTE = Front Office Full-Time Equivalent; (5) NNM = net new money, for reporting banks. Includes funds from new and existing clients less funds withdrawn by existing and former clients, at period end. Includes inter-Group transfers.




# **Profitability & productivity**

#### Net Interest Income % (Loans + Deposits)




### **Operating Revenue / Front Office FTE**

#### **Operating Revenue / AuM**



## Pre-tax profit margin


#### **RoAE**



Notes: (1) Tricumen-normalised product definitions and allocations apply. (2) Operating revenue and pre-tax profit exclude oneoffs and credit expense/recovery/NPL provisions. Capital expenditure is included as accrued. All financials are shown in US\$. (3) In-scope: clients with AuM in excess of \$200k. (4) RoAE = Net Profit/Allocated Equity. (4) Positive values = outperformance; negative values=underperformance; missing values = N/M; an outlier; no Tricumen coverage; or not a significant competitor.



## Y/Y dynamics



Notes: (1) Tricumen-normalised product definitions and allocations apply. (2) Operating revenue and pre-tax profit exclude oneoffs and credit expense/recovery/NPL provisions. Capital expenditure is included as accrued. All financials are shown in US\$, (3) In-scope: clients with AuM in excess of \$200k. (4) RoAE = Net Profit/Allocated Equity. (5) Positive values = outperformance; negative values=underperformance; missing values = N/M; an outlier; no Tricumen coverage, or not a significant competitor. (6) Net new money includes funds from new and existing clients less funds withdrawn by existing and former clients, at period end. Includes inter-Group transfers. Loans include clients' brokerage receivables.



### **About Tricumen**

Tricumen was founded in 2008. It quickly became a strong provider of diversified market intelligence across the capital markets and has since expanded into transaction and corporate banking, asset servicing, and asset and wealth management. Tricumen's data has been used by many of the world's leading investment banks as well as strategy consulting firms, investment managers and 'blue chip' corporations.

Situated near Cambridge in the UK, Tricumen is almost exclusively staffed with senior individuals with an extensive track record of either working for or analysing banks; and boasts what we believe is the largest financial markets-focused research network of its peer group.

## **Notes & Caveats**

Tricumen Limited places no restrictions on reproduction or transmission of data contained in this report, provided that information released is sourced to Tricumen Limited and that it does not prejudice Tricumen Limited's business or compromise the company's ability to analyse the financial markets. Full acknowledgement of Tricumen Limited must be given.

Tricumen Limited has used all reasonable care in writing, editing and presenting the information found in this report. All reasonable effort has been made to ensure the information supplied is accurate and not misleading. For the purposes of cross- market comparison, all numerical data is normalised in accordance to Tricumen Limited's proprietary product classification. Fully-researched dataset may contain margin of error of 10%; for modelled datasets, this margin may be wider.

The information and commentary provided in this report has been compiled for informational purposes only. We recommend that independent advice and enquiries should be sought before acting upon it. Readers should not rely on this information for legal, accounting, investment, or similar purposes. No part of this report constitutes investment advice, any form of recommendation, or a solicitation to buy or sell any instrument or to engage in any trading or investment activity or strategy. Tricumen Limited does not provide investment advice or personal recommendation nor will it be deemed to have done so.

Tricumen Limited makes no representation, guarantee or warranty as to the suitability, accuracy or completeness of the report or the information therein. Tricumen Limited assumes no responsibility for information contained in this report and disclaims all liability arising from negligence or otherwise in respect of such information.

Tricumen Limited is not liable for any damages arising in contract, tort or otherwise from the use of or inability to use this report or any material contained in it, or from any action or decision taken as a result of using the report.

© Tricumen Limited 2025. All rights reserved